Condition

Non-small Cell Carcinoma

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 17 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials17
Recruiting4
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

17 shown
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29
RECRUITING
Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung CancerNCT06057766 · 2024-01-01
RECRUITING
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid TumoursNCT05752552 · 2022-12-20
RECRUITING
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)NCT05657873 · 2022-12-09
RECRUITING
Combining ICI With SBRT or HypoFrx-RT for ES NSCLCNCT05451173 · 2023-10-09
UNKNOWN
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117 · 2023-06-13
TERMINATED
Investigating the Feasibility of a Physical Activity (tele)coaching Intervention in Patients with Non-small Cell Lung Cancer: an Explorative StudyNCT05569291 · 2022-10-01
COMPLETED
Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer PatientsNCT05319886 · 2022-05-16
UNKNOWN
Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLCNCT05007769 · 2021-10-31
WITHDRAWN
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung CancerNCT04791839 · 2021-08-04
ACTIVE_NOT_RECRUITING
Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 MutationsNCT04695925 · 2021-03-29
ACTIVE_NOT_RECRUITING
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung CancerNCT04364048 · 2020-06-18
TERMINATED
Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung CancerNCT03991819 · 2019-09-20
ACTIVE_NOT_RECRUITING
A Study of RGX-104 in Patients With Advanced Lung & Endometrial CancerNCT02922764 · 2016-11-01
COMPLETED
Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung CancerNCT03394105 · 2016-07-26
COMPLETED
Safety Study of SEA-CD40 in Cancer PatientsNCT02376699 · 2015-02-28
TERMINATED
Vaccine Treatment for Advanced Non-Small Cell Lung CancerNCT00073398 · 2003-11-01
COMPLETED

Common interventions

Trial status mix

COMPLETED4
RECRUITING4
ACTIVE_NOT_RECRUITING3
TERMINATED3
UNKNOWN2
WITHDRAWN1

Phase mix

PHASE28
PHASE16
NA2
PHASE32
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.